Celularity Inc., a biotechnology company specializing in placental-derived allogeneic cell therapies and biomaterial products, has announced that it will present data on its proprietary extracellular matrices (ECM) at the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE), taking place from July 24-26 in Osaka, Japan.
The data includes benchtop and clinical case studies for three of Celularity’s human placental-derived advanced biomaterial products: Biovance®, Biovance® 3L, and Interfyl®.
Benchtop data shows that Biovance®, a decellularized, dehydrated human amniotic membrane (DDHAM), modulates macrophage behavior, promotes polarization into M2 phenotype, and serves as a scaffold for endogenous cell attachment and proliferation in wound healing.
Biovance® 3L, a tri-layer DDHAM, supports human corneal epithelial cell activity and attenuates an inflammatory response over time. Interfyl®, a human connective tissue matrix (CTM), supports tenocyte viability, proliferation, and migration, while also maintaining phenotype and attenuating the inflammatory response.
CTM also serves as a scaffold for the attachment and proliferation of several cell types, including fibroblasts, monocytes, and endothelial cells, and permits monocyte differentiation into macrophages and vascular tube formation by endothelial cells.
Clinical case studies have used DDHAM in tendon repair and wound healing, DDHAM-3L in the treatment of anterior basement membrane dystrophy, and CTM to treat wounds and support the repair of soft tissues. However, additional clinical trials are needed to compare the outcomes associated with different biomaterial scaffolds in specific therapeutic applications.
Celularity’s biomaterial products are manufactured using a proprietary decellularization process that removes all residual cellular components, cells, cell debris, DNA, growth factors, and cytokines, while retaining the innate collagen framework with essential ECM molecules in its native three-dimensional form.
The company believes this unique proprietary process provides superior biocompatibility and better supports differentiated cell functions compared to other human placental-derived biomaterials which may contain cellular residuals.